Our site uses cookies to make navigation as functional as possible, including "third party" cookies and "profiling cookies" designed to tailor on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here. If you proceed browsing this website, you will be consenting to the use of all cookies.
11 Oct 2018

The MENARINI GROUP Announces Commercial Agreement for Vabomere, Orbactiv and Minocin in 68 Countries

  • Expands on existing commercial and co-development agreement for delafloxacin
  • Consolidates company’s strategic focus on infectious diseases

 

FLORENCE, Italy, October 11, 2018 -   The Menarini Group, an Italian biopharmaceutical company present in 136 countries worldwide, and Melinta Therapeutics, a US company dedicated to the discovery, development and commercialization of novel antibiotics to treat serious bacterial infections,  have announced an agreement under which Menarini will acquire the exclusive rights to commercialize meropenem/vaborbactam (VabomereTM in the US), oritavancin (Orbactiv®) and minocycline IV (Minocin IV®) in 68 countries in Europe, in Asia-Pacific including China, South Korea, and Australia (Japan excluded), and in the Commonwealth of Independent States (CIS) including Russia.

This agreement builds on Melinta and Menarini’s existing commercial and co-development agreement for  delafloxacin  – announced in 2017 – in the same 68 markets.

“We are excited to expand our partnership with the Menarini Group and significantly increase global access to our dynamic antibiotic portfolio,” said Dan Wechsler, President and CEO of Melinta.

“We at Menarini welcome this opportunity to continue our collaboration with Melinta which will further strengthen our presence in the infectious disease market,” declared Pio Mei, General Manager of the Menarini Group.  “The addition of meropenem/vaborbactam, oritavancin and minocycline IV to our current portfolio bolsters our high-value antibiotic platform in support of our mission, “Infection in Focus,” aimed at fighting life-threatening bacterial diseases which are an increasing global concern.”

The marketing authorization application for meropenem/vaborbactam is currently under review by EMA. On 20 September 2018, the Committee for Medicinal Products for Human Use (CHMP) expressed its positive opinion, recommending the granting of a marketing authorisation for the medicinal product  intended for the treatment of complicated intra-abdominal and urinary tract infections, hospital-acquired pneumonia, bacteraemia that occurs in association with any of these infections and infections due to aerobic gram-negative organisms where treatment options are limited. Orbactiv, a long acting lipoglycopeptide, has been approved by EMA in the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible designated gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA).


QUALITY FIRST

 
 

Quality: point of departure and arrival for our drugs.

READ MORE »